You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

~ Buy the VARITHENA (polidocanol) Drug Profile, 2024 PDF Report in the Report Store ~

VARITHENA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Varithena patents expire, and when can generic versions of Varithena launch?

Varithena is a drug marketed by Provensis and is included in one NDA. There are four patents protecting this drug.

This drug has ninety-seven patent family members in thirty countries.

The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this compound. Additional details are available on the polidocanol profile page.

DrugPatentWatch® Generic Entry Outlook for Varithena

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 12, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VARITHENA?
  • What are the global sales for VARITHENA?
  • What is Average Wholesale Price for VARITHENA?
Summary for VARITHENA
Drug patent expirations by year for VARITHENA
Drug Prices for VARITHENA

See drug prices for VARITHENA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VARITHENA
Generic Entry Date for VARITHENA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VARITHENA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OhioHealthPhase 4
BTG International Inc.Phase 4
Boston Scientific CorporationPhase 4

See all VARITHENA clinical trials

US Patents and Regulatory Information for VARITHENA

VARITHENA is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VARITHENA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VARITHENA

Therapeutic foam
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

Apparatus and method for dispensing foam
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

Apparatus and method for dispensing foam
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Aerosol valve
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-002 Dec 21, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VARITHENA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Sign Up ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Sign Up ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Sign Up ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Sign Up ⤷  Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VARITHENA

When does loss-of-exclusivity occur for VARITHENA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 09863
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 12530
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 45533
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 45533
Patent: VALVE POUR AEROSOL (AEROSOL VALVE)
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 45533
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 45533
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 66399
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VARITHENA around the world.

Country Patent Number Title Estimated Expiration
Denmark 2759291 ⤷  Sign Up
Austria 356613 ⤷  Sign Up
Cyprus 1110513 ⤷  Sign Up
Argentina 027175 GENERACION DE MICROESPUMA TERAPEUTICA ⤷  Sign Up
Japan 4731483 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.